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bound (UCB) for the mean ∆∆QTcF was <10 ms for all time 
points. An exposure–response analysis was also performed.
Results Forty-seven patients were enrolled. Maximum 
mean ∆∆QTcF of veliparib 400 mg was 6.4 ms, with a 
95 % UCB of 8.9 ms; for veliparib 200 mg, the maximum 
mean ∆∆QTcF was 3.6 ms, with a 95 % UCB of 6.1 ms. 
No patient had a QTcF value >480 ms or change from 
baseline in QTcF interval >30 ms. Treatment-emergent 
adverse events (TEAEs) were experienced by 36.2, 48.9, 
and 47.8 % of patients while receiving veliparib 200 mg, 
veliparib 400 mg, and placebo, respectively. Most common 
TEAEs were nausea (12.8 %) and myalgia (8.5 %) after 
veliparib 200 mg, nausea (8.5 %) and vomiting (8.5 %) 
after veliparib 400 mg, and nausea (6.5 %) after placebo.
Conclusions Single-dose veliparib (200 mg or 400 mg) 
did not result in clinically significant QTc prolongation and 
was well tolerated in patients with advanced solid tumors.
Keywords Veliparib · Poly(ADP-ribose) polymerase · 
PARP inhibitor · QT interval · ECG · Solid tumor
Introduction
Tumor cells are commonly deficient in DNA repair pro-
cesses. The resulting genomic instability not only fosters 
tumorigenesis, but also provides an opportunity for thera-
peutic intervention [1]. The poly(ADP-ribose) polymerase 
(PARP) protein family comprises more than 15 enzymes 
involved in a variety of cellular processes. PARP-1 and 
PARP-2 are crucial for single-strand DNA repair through 
the base excision repair pathway [2]. PARP inhibitors are 
a class of antineoplastic agents that target PARP-mediated 
DNA repair pathways, resulting in failure of base exci-
sion repair to correct single-strand breaks in DNA [2]. 
Abstract 
Purpose Veliparib (ABT-888) is an orally bioavailable 
potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1 
and PARP-2. This phase 1 study evaluated the effect of 
veliparib on corrected QT interval using Fridericia’s for-
mula (QTcF).
Methods Eligible patients with advanced solid tumors 
received single-dose oral veliparib (200 mg or 400 mg) or 
placebo in a 6-sequence, 3-period crossover design. The 
primary endpoint was the difference in the mean baseline-
adjusted QTcF between 400 mg veliparib and placebo 
(∆∆QTcF) at six post-dose time points. Absence of clinically 
relevant QTcF effect was shown if the 95 % upper confidence 
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Single-strand breaks eventually lead to double-strand 
breaks, which are commonly repaired by the error-free 
homologous recombination (HR) system. However, in 
tumors with defects in the HR repair machinery (i.e., 
tumors carrying BRCA1 and BRCA2 mutations), repair of 
the double-strand breaks becomes error-prone, leading to 
non-viable genetic errors and eventual cell death. PARP 
inhibitors have shown single-agent activity against solid 
tumors lacking a functional HR system, and also demon-
strate activity in combination with chemotherapy in a num-
ber of tumor types [2, 3].
Veliparib (ABT-888) is an orally bioavailable, potent 
inhibitor of PARP-1 and PARP-2 [4] that delays the repair of 
chemo- or radiotherapy-induced DNA damage [5–8]. Addi-
tionally, veliparib might generate stable PARP-1/2 complexes 
at the site of DNA damage that may exceed the cytotoxic-
ity of unrepaired single-strand breaks associated with PARP 
inhibition [9, 10]. In preclinical studies, veliparib was shown 
to increase the sensitivity of a variety of tumors to temozo-
lomide, cisplatin, carboplatin, and cyclophosphamide, while 
also demonstrating the ability to cross the blood–brain bar-
rier [4]. In a phase 1 study of patients with BRCA1/2-mutated 
or wild-type tumors, the maximum tolerated dose of single-
agent veliparib was 400 mg twice daily [11]. Dose-limiting 
toxicities at this dose level were grade 3 nausea/vomiting and 
grade 2 seizure in patients with BRCA1/2-mutated and wild-
type tumors, respectively. Several phase 3 trials of veliparib 
are ongoing in patients with solid tumors [12]. Two studies 
are evaluating veliparib in combination with carboplatin and 
paclitaxel as the first-line chemotherapy treatment of patients 
with advanced or metastatic non-small cell lung cancer 
(NCT02106546, NCT02264990). This combination is also 
being assessed in patients with human epidermal receptor 
2 (HER2)-negative advanced breast cancer carrying delete-
rious BRCA1/2 mutations (NCT02163694), and in patients 
with newly diagnosed advanced ovarian, primary peritoneal, 
and fallopian tube cancers (NCT02470585). An additional 
study in patients with early stage triple-negative breast can-
cer is evaluating the addition of veliparib combined with 
carboplatin compared to the addition of carboplatin to stand-
ard therapy versus standard chemotherapy (NCT02032277). 
Finally, veliparib is being assessed in combination with 
temozolomide in patients with newly diagnosed glioblas-
toma (NCT02152982). Veliparib doses of up to 150 mg 
twice daily were evaluated in combination with other treat-
ments in those studies.
Preclinical studies in dogs revealed a mild but concen-
tration-dependent increase in corrected QT (QTc) interval 
by veliparib. However, the clinical relevance of this finding 
was not clear. International Conference for Harmonisation 
(ICH) E14 guidance for the clinical evaluation of QT/QTc 
interval prolongation defines a threshold level for clinically 
relevant effect as the upper bound of the 95 % confidence 
interval around the mean effect on QTc of 10 ms (ICH, 
2005, 2015) [13, 14]. In this study, the effect of single-
dose veliparib administration at doses of 200 mg and 400 
mg on cardiac repolarization was compared with placebo in 
patients with advanced solid tumors.
Materials and methods
Study design and patients
This was a multicenter phase 1, single-dose, double-blind, 
placebo-controlled, randomized, 3-period, 6-sequence 
crossover study (NCT02009631). The primary objec-
tive was to evaluate the effect of veliparib on corrected 
QT interval using Fridericia’s formula (QTcF) in patients 
with solid tumors. Secondary objectives were to assess the 
pharmacokinetics, safety, and tolerability of single-dose 
veliparib.
Patients ≥18 years of age with a histologically or cyto-
logically confirmed metastatic or unresectable solid tumor for 
which standard curative measures or other therapy that may 
have provided clinical benefit did not exist or were no longer 
effective were eligible. Patients with brain metastases were 
required to have clinically controlled neurologic symptoms. 
All patients were required to have an Eastern Cooperative 
Oncology Group (ECOG) performance score of ≤1 be able 
to receive oral medication, and have adequate bone marrow, 
renal, and hepatic function. Exclusion criteria were as fol-
lows: QTcF > 470 ms at screening or baseline; electrocardio-
gram (ECG) abnormalities that would not allow for reliable 
QTc assessment; inadequate serum potassium, magnesium, 
or calcium, or free thyroxine (FT4) and thyroid-stimulating 
hormone outside the normal range, or grade 2 hyponatremia 
or hypernatremia; history of cardiac conduction abnormali-
ties; history of significant cardiovascular disease; blood pres-
sure and heart rates outside the normal range; history of, or an 
active medical condition that affected absorption or motility; 
had received anticancer therapy within the previous 21 days 
prior to the first dose of study drug or recovered to no bet-
ter than grade 2 clinically significant adverse event (AE) of 
the previous therapy; or used drugs with a known risk of QT 
prolongation and Torsades de Pointes within 7 days before 
the first study dose. All patients were required to provide their 
signed informed consent. The study received Independent 
Ethics Committee and Institutional Review Board approval, 
and was conducted in compliance with the Declaration of 
Helsinki and ICH Good Clinical Practice guidelines.
Treatment
Following screening, on the morning of day 1 of each 
period, eligible patients received a single dose of veliparib 
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200 mg, veliparib 400 mg, or placebo according to the 
treatment sequence assigned at randomization, adminis-
tered orally between 8.00 and 10.00 am, and approximately 
30 min after the start of a low-fat breakfast. Each treatment 
period lasted 3–7 days, allowing for ≥3 days of drug wash-
out between periods. After study completion, patients were 
permitted to enter an extension study (NCT02033551) to 
assess the safety of veliparib as monotherapy or in combi-
nation with chemotherapy.
During the study, patients were required to be on sta-
ble doses of permitted medications or replacement sup-
plements ≥14 days prior to receiving the first study dose. 
Vitamins and/or herbal supplements were not permitted 
unless required for a patient’s medical condition. Patients 
who were taking replacement supplements such as cal-
cium, magnesium, or potassium were allowed to continue 
on these supplements. Medications with a known risk of 
QT prolongation and Torsades de Pointes were not allowed, 
including serotonin receptor antagonists, due to the poten-
tial for cardiovascular interactions, with the exception of 
palonosetron. Colony-stimulating factor or human erythro-
poietin use was permitted along with supportive prophylac-
tic drugs unless specifically excluded by the study protocol.
ECG assessments
Serial, resting 12-lead ECG measurements were performed 
at screening, on day 1 of each period at 0 h (pre-dose), and 
at 0.5, 1, 2, 3, 10, and 24 h post-dose, and at the final study 
visit on day 3 of period 3. ECGs were performed in triplicate 
except for a single ECG at screening. All ECG tracings were 
evaluated using the automated signal analysis algorithm of 
eECG/ABBIOS to measure predefined ECG intervals (RR, 
PR, QT, and QRS duration). All ECGs were manually verified 
and adjudicated by an expert over-reader who was blinded to 
treatment, time, and patient identification. T- and U-wave mor-
phologies were independently reviewed by a qualified cardiol-
ogist who was similarly blinded to treatment, time, and patient 
identification. QTcF was determined as follows:
A linear mixed effects model was used for the analysis 
of baseline-adjusted QTcF intervals (∆QTcF) for the first 
24 h after dosing with either placebo, veliparib 200 mg, or 
veliparib 400 mg. The primary endpoint was the baseline-
adjusted difference in mean QTcF between the veliparib 
400 mg dose and placebo (∆∆QTcF) at six post-dose time 
points. Absence of QTcF effect was established if the 95 % 
upper confidence bound for the mean ∆∆QTcF between 
veliparib 400 mg and placebo was below the 10 ms thresh-
old of clinical significance for all post-dose time points, in 






QTc, PR, and QRS interval variables, appropriate cutoff 
points defining the categories of the largest change from 
baseline were determined. For QTc, the cutoff points for 
these categories were as specified in the ICH E14 guide-
lines. The dataset for ECG evaluations included all avail-
able patients’ data.
Pharmacokinetic assessments
In each period, blood samples were collected for phar-
macokinetic analysis at 0 h (pre-dose), and at 0.5, 1, 2, 
3, 10, and 24 h post-dose. Plasma concentrations of veli-
parib were determined using a validated online solid-phase 
extraction followed by liquid chromatography with tandem 
mass spectrometric detection with a lower limit of quanti-
tation for veliparib of 1.05 ng/mL. Veliparib pharmacoki-
netic parameters were estimated using non-compartmental 
methods.
Exposure–response model
To establish the nonsignificance of a hysteresis effect, the 
criteria discussed in Darpo et al. [15] were applied. Sub-
sequently, linear mixed effects models were tested, with or 
without an additional lagged effect compartment, depend-
ing on the outcome of the test for hysteresis. A final model 
was chosen based on goodness of fit, plausibility of the 
parameters, and Bayesian information criterion (BIC). The 
relationship between ∆∆QTcF and veliparib concentration 
was modeled using the following equation:
for subject i and time point j. η(2) represents the inter-sub-
ject variability on intercept (fixed effect on intercept is set 
to zero). Slope0 represents fixed effect on slope. η
(1) rep-
resents the inter-subject variability of the Slope. εi,j is the 
residual variability in subject i at time j.
Safety
Safety was evaluated by AE monitoring, vital signs, physi-
cal examination, and laboratory testing throughout the 
study. Treatment-emergent AEs (TEAEs) were recorded 
from the time of first dose of study drug until 30 days 
from the last day of dosing or discontinuation, or until 
the first dose of study drug for patients enrolling in the 
NCT02033551 extension study. TEAEs were classified by 
Medical Dictionary for Regulatory Activities version 17.0 
system organ class and preferred term. The severity of AEs 
was rated according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 4.0. 
The safety population consisted of all patients’ data.
��QTcFi,j = η
(2)
i + (Slope0 + η
(1)
i )× Concentrationi,j + εi,j
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Sample size calculation
For the sample size calculation, it was assumed that veli-
parib 400 mg would be associated with mean QTcF values 
higher than placebo by 2–4 ms at each of the six post-dose 
time points. The standard deviation (SD) of QTcF in oncol-
ogy patients was assumed to be 20 ms. Complete data from 
36 patients would yield 85 % power to demonstrate that the 
veliparib 400 mg regimen compared to placebo would have 
no clinically relevant effect on QTc interval (i.e., the 95 % 
upper confidence bound for the mean ∆∆QTcF would 
be <10 ms for all six post-dose time points). The target 
sample size was 48 patients, to allow for potential prema-
ture discontinuations and to account for missing or uneval-
uable ECG measurements.
Results
Patient disposition and demographics
Forty-seven patients were enrolled and randomized to the 
sequence groups shown in Table 1. Patient demographics 
and baseline characteristics are summarized in Table 1. 
Patients had a median age of 58.0 years (range, 34–80), 
with most patients aged <65 years (72.3 %). The majority 
of patients were female (85.1 %) and white (95.7 %). One 
patient prematurely discontinued after receiving the veli-
parib 200 mg–veliparib 400 mg sequence, and not placebo, 
due to AEs considered by the investigator to have no rela-
tionship to study drug.
ECG
The mean (+SD) QTcF and mean (+SD) ∆QTcF inter-
val-versus-time profiles on day 1 for veliparib 400 mg, 
veliparib 200 mg, and placebo are shown in Fig. 1a and b, 
respectively. No patient while receiving any of the three 
regimens had a QTcF value greater than 480 ms, and no 
patient had a change from baseline in QTcF interval greater 
than 30 ms. Following a single dose of veliparib 400 mg, 
the maximum 95 % upper confidence bound for mean 
∆∆QTcF was 8.9 ms, with estimates of the mean drug 
effect ranging from 0.6 ms to 6.4 ms at different post-dose 
time points. For veliparib 200 mg, the maximum 95 % 
upper confidence bound for mean ∆∆QTcF was 6.1 ms, 
with estimates of mean drug effect at different post-dose 
time points ranging from 0.6 to 3.6 ms (Fig. 1c). Therefore, 
a lack of effect on QTcF interval prolongation was demon-
strated for the clinical doses of veliparib [13].
Table 1  Patient demographics and baseline characteristics
A single-dose veliparib 200 mg, B single-dose veliparib 400 mg, C placebo, ECOG Eastern Cooperative Oncology Group, SD standard deviation
a For each regimen sequence: the letter in the first position denotes the study drug administered in period 1, day 1; the letter in the second posi-
tion denotes the study drug administered in period 2, day 1; the letter in the third position denotes the study drug administered in period 3, day 1
b One patient was prematurely discontinued in period 3
Parameter Regimen sequencea Total N = 47
ABCb N = 8 CAB N = 8 BCA N = 8 BAC N = 8 ACB N = 7 CBA N = 8
Female, n (%) 7 (87.5) 7 (87.5) 6 (75.0) 7 (87.5) 7 (100) 6 (75.0) 40 (85.1)
Race, n (%)
 White 8 (100) 8 (100) 8 (100) 8 (100) 7 (100) 6 (75.0) 45 (95.7)
 Black or African-American 0 0 0 0 0 1 (12.5) 1 (2.1)
 Asian 0 0 0 0 0 1 (12.5) 1 (2.1)
Age, years
 <65, n (%) 6 (75.0) 5 (62.5) 6 (75.0) 6 (75.0) 4 (57.1) 7 (87.5) 34 (72.3)
 ≥65, n (%) 2 (25.0) 3 (37.5) 2 (25.0) 2 (25.0) 3 (42.9) 1 (12.5) 13 (27.7)
 Mean (SD) 58.8 (11.0) 60.8 (10.0) 56.0 (11.0) 59.3 (6.5) 53.6 (14.1) 53.5 (13.3) 57.0 (10.9)
 Median (range) 58.0 (46–80) 62.0 (48–73) 51.5 (45–71) 60.0 (52–69) 58.0 (34–69) 52.5 (39–80) 58.0 (34–80)
Primary cancer, n
 Ovarian 6 5 3 7 3 2 26 (55.3)
 Breast 1 1 0 0 2 4 8 (17)
 Other 1 2 5 1 2 2 13 (27.7)
ECOG, n (%)
 0 5 6 7 4 4 3 29 (61.7)
 1 3 2 1 4 3 5 18 (38.3)
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ECG measurements in at least one time point were miss-
ing for 13 patients, with some patients missing all ECG 
replicates at a specific time point. However, since the miss-
ing data were dispersed throughout the dosing regimens 
and assessment time points, their effect on the conclusions 
was negligible.
Pharmacokinetics
Following single-dose oral administration of veliparib 
200 mg and veliparib 400 mg, systemic exposure to the 
drug increased in a dose-proportional manner, suggesting a 
linear pharmacokinetic profile. Consistent with this obser-
vation, the dose-normalized maximum concentration (Cmax/
dose) and area under the plasma concentration–time curve 
from time 0 to infinity (AUC∞/dose) values were similar 
between the two dose groups of veliparib (Table 2). Mean 
time to Cmax (Tmax) and terminal phase elimination half-life 
(t1/2) were similar for the two dose groups at approximately 
2.5 and 5.5 h, respectively. The mean plasma concentra-
tion-versus-time profiles for veliparib 200 mg and veliparib 
400 mg are shown in Fig. 2.
Exposure–response analysis
For the exposure–response model, hysteresis was ruled out 
using the criteria suggested by Darpo et al. [15]. A linear 
mixed effects model with mean intercept fixed to zero, link-
ing the observed concentration to ∆∆QTcF was found to 
give the best fit based on BIC. The model showed adequate 
goodness of fit, considering the variability of the data. The 
predicted mean and upper 95th percentile ∆∆QTcF at geo-
metric mean of Cmax in the 200 mg dosing were 2.45 and 
3.28 ms, respectively. For the 400 mg dosing, mean and 
upper 95th percentile ∆∆QTcF at geometric mean of Cmax 
































































Fig. 1  a QTcF and b baseline-adjusted QTcF (∆QTcF)a interval-
time profiles. Data are means + standard deviations. c Baseline-
adjusted drug-placebo difference in QTcF interval (∆∆QTcF). 
Data are point estimates plus 95 % upper-bound time profiles. 
aFour patients had missing baseline or all post-baseline ECG interval 
measurements and were not included in ∆QTcF analyses for the regi-
men in which the information was missing. ECG electrocardiogram, 
QTcF corrected QT interval using Fridericia’s formula
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Safety
A similar percentage of patients experienced a TEAE dur-
ing treatment with veliparib 200 mg, veliparib 400 mg, and 
placebo (Table 3). More patients who were administered 
veliparib 400 mg had a TEAE considered by the investiga-
tor to be at least possibly related to study drug when com-
pared to either veliparib 200 mg or placebo. The most com-
mon TEAEs reported in ≥2 patients in any dosing regimen 
were nausea (12.8 %) and myalgia (8.5 %) in the veliparib 
200 mg dose group, and nausea (8.5 %), vomiting (8.5 %), 
diarrhea (6.4 %), fatigue (6.4 %), and dizziness (6.4 %) in 
the veliparib 400 mg dose group (Table 4). In the placebo 
group, nausea (6.5 %) was the most common TEAE. Over-
all, nausea was the most common TEAE assessed as having 
a reasonable possibility of relationship to study drug.
One patient discontinued the treatment sequence prema-
turely after receiving veliparib 200 mg in period 1 and veli-
parib 400 mg in period 2, due to AEs of suicidal ideation and 
depression. The patient had a history of depression and had 
discontinued sertraline, an excluded medication, prior to the 
first period. Upon resuming sertraline, the events resolved. 
Both events were considered by the investigator to have no 
reasonable possibility of relationship to study drug. Two 
patients experienced a grade 3 TEAE, one each during treat-
ment with veliparib 200-mg and veliparib 400-mg. These 
events were vomiting and depression, and were considered 
by the investigator to have no relationship to study drug. No 
serious AEs or deaths were reported. No safety concerns 
were observed for any vital sign or biochemical parameter.
Discussion
Maintaining cardiac function in patients undergoing 
chemo- and radiotherapy is a concern in the development 
of any new drug. Advancements in molecular medicine 
have provided numerous rational targets for therapy, but 
in some cases, novel treatments such as tyrosine kinase 
inhibitors have shown the potential to interfere with cardiac 
repolarization and may therefore present an unacceptable 
risk to patients who are undergoing cancer treatment [16]. 
This QT study found no clinically relevant effect of clinical 
single doses of veliparib (200 mg and 400 mg) on QTcF 
prolongation per ICH E14 guideline [13, 14]. Consistently, 
the exposure–response analysis indicated lack of clinically 
relevant QT prolongation at observed plasma concentration 

























Veliparib 200 mg (N = 47)
Veliparib 400 mg (N = 46)
0 4 8 12 16 20 24
Fig. 2  Veliparib plasma concentration–time profile. Data are 
means + standard deviations; linear-log scale
Table 2  Pharmacokinetic parameters of veliparib following single-
dose oral administration
Data are mean ± SD
AUC∞ area under the plasma concentration–time curve from time 0 
to infinity, AUC∞/dose dose-normalized AUC∞, AUCt area under 
the plasma concentration–time curve from time 0 to time of the last 
measurable concentration, CL/F apparent oral clearance, Cmax maxi-
mum observed concentration, Cmax/dose dose-normalized Cmax, Tmax 
time to Cmax, SD standard deviation, t1/2 terminal phase elimination 
half-life, VZ/F apparent volume of distribution
a One patient experienced vomiting following veliparib administra-
tion and exhibited maximum concentrations 10 h post-dose and lower 
exposure by 1 order of magnitude compared to the rest of the patients 
in the 400 mg dose group; this patient was excluded from pharma-
cokinetic parameter summary statistics
b N = 46




200 mg 400 mg
N = 47 N = 46a
Cmax µg/mL 1.32 ± 0.378 2.61 ± 0.847
Tmax h 2.4 ± 0.7 2.5 ± 0.6
AUCt µg h/mL 11.1 ± 3.12 23.8 ± 7.1
AUC∞ µg h/mL 12.0 ± 3.98b 25.5 ± 8.37
t1/2
c h 5.3 ± 1.1b 5.4 ± 1.3
CL/F L/h 18.2 ± 5.09b 17.3 ± 5.27
VZ/F L 141 ± 42.8b 138 ± 48.4
Cmax/dose (ng/mL)/mg 6.62 ± 1.89b 6.51 ± 2.12
AUC∞/dose (ng h/mL)/mg 59.9 ± 19.9b 63.8 ± 20.9
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In this study, patients receiving single-dose veliparib 
achieved systemic exposure levels to the drug that were 
comparable with those observed in previous studies, as 
shown by values for dose-normalized Cmax and AUC∞ 
[17]. Furthermore, the present findings show that single-
dose veliparib at either the 200-mg or 400-mg dose is safe 
and well tolerated in patients with relapsed/refractory solid 
tumors.
Originally adopted in 2005 [13], the ICH E14 guidance 
on evaluating QT/QTc prolongation was deliberately not 
overly prescriptive, instead focusing on the need during 
drug development to conduct a “thorough QT/QTc study” 
[18]. With advances in both science and experience, the 
ICH has continued to issue updated guidance to overcome 
ambiguity and uncertainty in relation to the process, with 
its most recent update in 2015 [14]. In the development of 
anticancer agents to treat patients with advanced refrac-
tory cancer, deviations from the formal ICH E14 guideline 
have been accepted when the standard QT/QTc study is not 
feasible for safety or ethical reasons [19]. An alternative 
approach was used regarding two aspects of study design. 
First, the study was carried out in the absence of a positive 
control (such as moxifloxacin) for ethical reasons, to allow 
an advanced cancer population with no treatment alterna-
tive the opportunity to receive a potentially beneficial new 
cancer therapy without much delay. Second, the highest 
dose of study drug used was the veliparib 400 mg dose, 
which might not represent supra-therapeutic exposure. Veli-
parib 400 mg was chosen in this study for safety reasons, 
since it was determined to be the maximum tolerated dose 
of veliparib as single agent in the Puhalla et al. study [11]. 
Of note, the dose of veliparib used in the ongoing phase 
2 and 3 studies when in combination with chemotherapy 
ranges between 40 mg and 200 mg twice daily. Other than 
those two aspects, this study was designed and executed 
with standard attributes of a thorough QT study. Further-
more, the present study represents a successful example of 
a QT study performed in an oncologic patient population.
The data presented herein support the conclusion 
that veliparib does not result in clinically relevant QTc 
Fig. 3  Exposure–response 
model. Veliparib plasma 
concentration-∆∆QTcF predic-
tions; data represent median 
and upper 95 % confidence 
intervals. QTcF corrected QT 
interval using Fridericia’s 
formula, ∆∆QTcF baseline-
adjusted drug-placebo differ-
ence in QTcF interval
Table 3  Treatment-emergent 
adverse events (safety analysis 
dataset)
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, TEAE treat-
ment-emergent adverse event
a As assessed by investigator
b Includes non-treatment-emergent deaths
TEAE, n (%) Dosing regimen Overall
Veliparib Veliparib Placebo
200 mg 400 mg
N = 47 N = 47 N = 46 N = 47
Any AE 17 (36.2) 23 (48.9) 22 (47.8) 38 (80.9)
 At least possibly related to study druga 7 (14.9) 11 (23.4) 7 (15.2) 20 (42.6)
 NCI CTCAE grade 3 or 4 1 (2.1) 1 (2.1) 0 2 (4.3)
Any serious AE 0 0 0 0
AE leading to discontinuation 0 1 (2.1) 0 1 (2.1)
Any fatal AE 0 0 0 0
Deathsb 0 0 0 0
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prolongation in patients with advanced solid tumors. With 
an adequate sample size of 47 patients, the data had high 
precision in establishing the 95 % upper confidence bounds 
for mean ∆∆QTcF below the threshold of regulatory con-
cern at all post-dose time points. Moreover, there was no 
safety signal relating to abnormal cardiac repolarization 
based on the observed AEs, and the drug exposure levels 
achieved were consistent with previous reports of veliparib 
in patients with solid tumors.
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